BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review

BAY 81-8973 (Kovaltry(®)) is an unmodified, full-length recombinant factor VIII (rFVIII) approved for the prevention and treatment of bleeding episodes in patients with hemophilia A. The amino acid sequence for BAY 81-8973 is identical to that of sucrose-formulated rFVIII (rFVIII-FS; Kogenate(®) FS/...

Full description

Saved in:
Bibliographic Details
Published in:Ther Adv Hematol
Main Authors: Mahlangu, Johnny N., Ahuja, Sanjay P., Windyga, Jerzy, Church, Nikki, Shah, Anita, Schwartz, Lawrence
Format: Artigo
Language:Inglês
Published: SAGE Publications 2018
Subjects:
Reviews
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6041863/
https://ncbi.nlm.nih.gov/pubmed/30013766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620718777903
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items